Last reviewed · How we verify
NCT04764110
Short-term Impact of Cyplexinol® on Self-reported Joint Pain
NA trial testing Cyplexinol in Joint Pain in 18 participants. Completed in 28 January 2022.
28 January 2022
Quick facts
| Lead sponsor | University of Memphis |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 18 |
| Start date | 17 March 2021 |
| Primary completion | 28 January 2022 |
| Estimated completion | 28 January 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cyplexinol
- Placebo
Conditions studied
- Joint Pain — all drugs for Joint Pain →
Sponsor
University of Memphis
Who can join
Adults 30 to 65, any sex, with Joint Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo on days 1 and 15.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04764110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Joint Pain
Currently open trials in the same condition.
- NCT07179016 — Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populati · NA · recruiting
- NCT06863636 — Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation · Phase 3 · recruiting
- NCT05658575 — Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare · Phase 2, PHASE3 · recruiting
- NCT04994249 — Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation · active not recruiting
- NCT05621369 — Psorcast Mobile Study · recruiting
Other University of Memphis trials
Trials by the same sponsor.
- NCT07507344 — Beverage Hydration Index of Different Solutions · NA · recruiting
- NCT07215351 — Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women · NA · recruiting
- NCT06733532 — Comparison of the Beverage Hydration Index of Different Solutions · NA · completed
- NCT06318962 — Examining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors · NA · recruiting
- NCT06272435 — Beverage Hydration Index: Assessment of Four Rehydration Solutions · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04764110 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Memphis
- Last refreshed: 22 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04764110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing